RAMSAY DAVID A 4

What Happened David A. Ramsay, EVP and President, Drug Delivery at Halozyme Therapeutics (HALO), exercised/converted derivatives for 10,000 shares on 2026-06-30 and, in connection with vesting/settlement, received a total of 56,055 restricted stock units (16,232 + 39,823) on 2026-07-01. The filing shows 5,408 shares were withheld by the issuer to satisfy tax-withholding obligations, valued at $78.27 per share (total ~$423,284). The RSU shares were reported with $0 acquisition price as typical for vested awards; the withheld shares reflect a tax withholding, not an open-market sale.

Key Details

• Transaction dates: 2026-06-30 (derivative exercise/conversion) and 2026-07-01 (RSU settlement).
• Reported share movements: exercised/converted 10,000 derivative shares; RSU settlement of 16,232 and 39,823 shares (total 56,055); 5,408 shares withheld for taxes at $78.27/share (~$423,284).
• Prices/values: withholding calculated at $78.27 per share; RSUs and exercise shown with $0 acquisition price on the Form 4.
• Shares owned after transaction: not specified in the excerpt of the filing.
• Footnotes: F1 — withholding for tax obligations; F2 — RSU vesting/settlement and shares remain subject to a one‑year holding period from vesting; F3 — award vests 1/4 after one year then annually; F4 — option vests 1/4 after one year then monthly (1/48th).
• Filing timeliness: Form filed 2026-07-02 for transactions through 2026-06-30; filing appears to be within the usual two-business-day window.

Context This filing reflects routine option/RSU vesting and a tax-withholding event (issuer withheld shares to cover taxes). Withheld shares are a mechanical tax payment and not the same as an open-market sale signaling a change in insider sentiment. The RSU shares remain subject to a one-year holding restriction per the footnote.